Anixa Biosciences to Present at Biotech Showcase 2024
SAN JOSE, Calif., Dec. 14, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California in parallel to the 42nd Annual J.P. Morgan Healthcare Conference (“JPM Week 2024”).
Related news for (ANIX)
- Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences’ Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
- Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
- Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
- Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology